Page updated 7/1/09
| THE BIOFOUNDATION FOR ANGIOGENESIS RESEARCH AND DEVELOPMENT 501 (c) (3) ID # 31-6670928 A TAX EXEMPT FOUNDATION The foundation is committed to finding non invasive modalities to treat cancer by analysing "angiogenesis" r new blood vessel (angio) formation (genesis). o Major international symposiums (ISET2009, ARRS2008 and MICCAI2008) showed tumor blood vessel formation revealed by sonogram Doppler imaging was the best predictor of cancer aggression. Treatment success is validated when bnormal arteries decrease after therapy. a The foundation assesses and develops new MRI and ultrasound technologies to detect and treat cancer non invasively. Contributions to the foundation advance image guided therapeutic technologies. The foundation sponsors world wide teaching programs for physicians on new modalities to diagnose and deliver therapies for cancer and allied diseases. Make checks payable to: Biofoundation for Angiogenesis c/o Robert L. Bard, MD, DABR, MACR 121 East 60th Street Ste. 6A New York, N.Y. 10022 USA 212-355-7017 www.cancerscan.com **NEW IRS LAW ALLOWS IRA FUND DONATION WITHOUT TAX PENALTY** **CERTIFIED FINANCIAL STATEMENTS AVAILABLE FOR INSPECTION** **Dr. Bard is Editor: “MRI OF THE PROSTATE” SPRINGER 2008** 2009 Prostate Cancer Newsletter DR BARD authored: “MRI ATLAS OF PROSTATE CANCER” Springer 2009 PSA PSA-NOT RECOMMENDED BY 2008 AMERICAN COLLEGE PREVENTIVE MEDICINE 0% (ZERO %) SPECIFICITY-CANCER DETECTED EVEN WITH 0 PSA READING MOST AGGRESSIVE TUMORS (ANAPLASTIC) DO NOT RAISE PSA LEVELS IMAGING PROSTASCINT, PET, CT, MRI AND BONE SCANS-LOW SPECIFICITY POWER DOPPLER ULTRASOUND - 90% ACCURACY 3-DIMENSIONAL POWER DOPPLER SONOGRAPHY - 95% ACCURACY COMPUTER AIDED DYNAMIC CONTRAST ENHANCED (DCE) MRI - 96% ACCURACY 3-D (18.3 MHz) SONOGRAM DIFFERENTIATES CANCER FROM PROSTATITIS (detects capsular erosion, penetration and tumor vascularity) TUMOR AGGRESSION HIGH BLOOD FLOW (DOPPLER or MRI) = HIGH AGGRESSION DECREASED TUMOR BLOOD FLOW=SUCCESSFUL THERAPEUTIC OUTCOME T UMOR SIZE CHANGE NOT SPECIFIC=DYING CANCER CELLS CAN ENLARGE NON - INVASIVE THERAPIES HIFU (HIGH INTENSITY FOCUSED ULTRASOUND)-70% 11 YEAR CURE RATE ANTIOXIDANT PROTOCOLS-80% TUMOR STABILIZATION-4 YEAR DATA References: DR BARD: INTERNATIONAL SOCIETY ENDOVASCULAR THERAPY - 2009 DR BARD: AMERICAN ROENTGEN SOCIETY – 2009 SCIENTIFIC SESSION R OYEN: EUROPEAN CONGRESS RADIOLOGY – 2009 SCIENTIFIC SESSION D POST THERAPY HIGH GRADE TUMOR DR BARD 121 E 60 ST NY NY 10022 212-355-7017 www.cancerscan.com |
 |
| |
 |
| |
 |
Lymphland International Lymphedema Online
